Amiodarone and implantable cardioverter-defibrillators in congestive heart failure

D Böcker1, M Block1, W Haverkamp1

  • 1Universitätsklinik Münster, Medizinische Klinik C, D-48129 Münster, Germany, Email: bockerd@uni-muenster.de, Germany.

Zeitschrift Fur Kardiologie
|June 21, 2016
PubMed

Insights

Sudden cardiac death is a major concern in heart failure patients. Amiodarone and implantable cardioverter-defibrillators (ICDs) show promise in reducing this risk, with current data being reviewed.

Area of Science:

  • Cardiology
  • Clinical Medicine
  • Pharmacology

Background:

  • Sudden death represents a significant mortality cause in heart failure patients.
  • Current therapeutic options for heart failure management are diverse.
  • Reducing sudden cardiac death is a critical goal in heart failure treatment.

Purpose of the Study:

  • To review and compare the efficacy of amiodarone and implantable cardioverter-defibrillators (ICDs) in preventing sudden death in heart failure patients.
  • To synthesize current evidence on the roles of amiodarone and ICDs in managing heart failure outcomes.
  • To provide an overview of the available information regarding these two interventions.

Main Methods:

  • Literature review of existing studies and clinical data.
  • Comparative analysis of amiodarone and ICD therapy.
  • Synthesis of evidence on sudden death reduction in heart failure.

Main Results:

  • Both amiodarone and ICDs demonstrate potential in reducing sudden death.
  • The relative effectiveness and specific indications for each therapy are under ongoing investigation.
  • Further research is needed to fully elucidate the comparative benefits.

Conclusions:

  • Amiodarone and ICDs are key therapeutic strategies for mitigating sudden death risk in heart failure.
  • The choice between amiodarone and ICDs depends on individual patient factors and clinical guidelines.
  • Continued evaluation of these interventions is crucial for optimizing heart failure care.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
725
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
511
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
478